Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-09-27
2000-01-11
Wortman, Donna
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
A01N 4304
Patent
active
060136413
ABSTRACT:
A pharmaceutical formulation of hyaluronic acid is administered to a patient suffering from undesirable T cellactivity. The hyaluronic acid inhibits T cell activity at doses that are well-tolerated by the recipient. Conditions suitable for treatment include graft vs. host disease, graft rejection and certain autoimmune diseases having a T cell component.
REFERENCES:
patent: 5356883 (1994-10-01), Kuo et al.
Chevrier et al., "Inhibition of active E rosette forming T lymphocytes by hyaluronic acid--evidence of a receptor for hyaluronic acid on a lymphocyte subpopulation", Biomedicine 1982; 36:100-103, 1982.
Angeleri, M.L., et al., "Terapia Immunosoppressiva Nella Prevenzion Del Rigetto Del Trapianto Corneale", Arch. Med. Interna.,43(2):81-85 (1991).
Gowland, G. et al., "Marked Echanced Efficacy of Cyclosporin When Combined With Hyaluronic Acid", Clin. Drug Invest. 11(4):245-250 (1996).
Bartolazzi, A. et al., "Interaction between CD44 and Hyaluronate is Directly Implicated in the Regulation of Tumor Development," J. Exp. Med., 180:53-66 (1994).
Knudson, C.B. and W. Knudson, "Hyaluronan-Binding Proteins in Development, Tissue Homeostasis, and Disease," The FASEB Journal, 7(13) : 1233-1239 (1993).
Delfino, D.V. et al. "Role of CD44 in the Development of Natural Killer Cells from Precursors in Long-Term Cultures of Mouse Bone Marrow," Journal of Immunology, 152(11):5171-5179 (1994).
Lesley, J. et al., "Hyaluronan Binding Function of CD44 is Transiently Activated on T Cells During an In Vivo Immune Response," J. Exp. Med., 180:383-387 (1994).
Kimura, K. et al., "Role of Glycosaminoglycans in the Regulation of T Cell Proliferation Induced by Thymic Stroma-Derived T Cell Growth Factor," The Journal of Immunology, 146:2618-2624 (1991).
Galdandrini, R. et al., "Hyaluronate is Costimulatory for Human T Cell Effector Functions and Binds to CD44 on Activated T Cells," The Journal of Immunology, 153:21-31 (1994).
Funaro, A. et al., "Stimulation of T Cells Via CD44 Requires Leukocyte-Function-Associated Antigen Interactions and Interleukin-2 Production," Human Immunology, 40:267-278 (1994).
Buelow Roland
Lussow Alexander R.
Brumback Brenda G.
Lorenz Todd A.
SangStat Medical Corporation
Trecartin Richard F.
Wortman Donna
LandOfFree
Use of hyaluronic acid as an immunosuppressant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hyaluronic acid as an immunosuppressant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hyaluronic acid as an immunosuppressant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1462485